Prevalence and patterns of use of psychoactive medicines in individuals with autism in the autism society of North Carolina

被引:81
作者
Langworthy-Lam, KS
Aman, MG
Van Bourgondien, ME
机构
[1] Ohio State Univ, Nisonger Ctr Mental Retardat & Dev Disabil, Columbus, OH 43210 USA
[2] Univ N Carolina, Div TEACCH, Chapel Hill, NC USA
关键词
D O I
10.1089/104454602762599853
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
The aim of this study was to assess the prevalence and patterns of psychoactive and over-the-counter medicines in a large cohort of individuals with autism. We conducted a mail survey of 3,228 families that are members of the Autism Society of North Carolina. This is one of the largest chapters of the Autism Society of America. The survey form addressed current medicines used, side effects, demographic characteristics, and medical conditions. Some 1,538 member families within the society (48%) responded to the survey. In all, 703 (45.7%) individuals with autism were taking psychotropic drugs, 191 (12.4%) antiepileptic drugs (AEDs), and 86 (5.7%) supplements for autism. The total number taking psychotropic, antiepileptic, or vitamin treatments was 816 (53.1%). Antidepressants (taken by 21.7% of the sample), anti-psychotics (16.8%), and stimulants (13.9%) were the most commonly prescribed agents. Univariate and multivariate analyses were conducted to examine factors associated with treatment. Greater age, more severe autism and mental retardation, and more restricted housing were often associated with greater use of psychoactive agents. These findings suggest that individuals with autism are a frequently medicated group, although the empirical research support for most agents being used is still very limited.
引用
收藏
页码:311 / 321
页数:11
相关论文
共 23 条
[1]  
Aman MG, 1999, MENT RETARD DEV D R, V5, P279, DOI 10.1002/(SICI)1098-2779(1999)5:4<279::AID-MRDD5>3.0.CO
[2]  
2-6
[3]   PSYCHOTROPIC AND ANTICONVULSANT DRUGS IN SUBJECTS WITH AUTISM - PREVALENCE AND PATTERNS OF USE [J].
AMAN, MG ;
VANBOURGONDIEN, ME ;
WOLFORD, PL ;
SARPHARE, G .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1995, 34 (12) :1672-1681
[4]   CLINICAL EFFECTS OF METHYLPHENIDATE AND THIORIDAZINE IN INTELLECTUALLY SUBAVERAGE CHILDREN [J].
AMAN, MG ;
MARKS, RE ;
TURBOTT, SH ;
WILSHER, CP ;
MERRY, SN .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1991, 30 (02) :246-256
[5]  
Aman MG, 1999, MENT RETARD DEV D R, V5, P253, DOI 10.1002/(SICI)1098-2779(1999)5:4<253::AID-MRDD2>3.3.CO
[6]  
2-I
[7]  
AMAN MG, IN PRESS J AUTISM DE
[8]  
[Anonymous], DIET REF INT RISK AS
[9]   FLUOXETINE TREATMENT OF CHILDREN AND ADULTS WITH AUTISTIC DISORDER AND MENTAL-RETARDATION [J].
COOK, EH ;
ROWLETT, R ;
JASELSKIS, C ;
LEVENTHAL, BL .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1992, 31 (04) :739-745
[10]   High-dose pyridoxine and magnesium administration in children with autistic disorder: An absence of salutary effects in a double-blind, placebo-controlled study [J].
Findling, RL ;
Maxwell, K ;
ScoteseWojtila, L ;
Huang, J ;
Yamashita, T ;
Wiznitzer, M .
JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS, 1997, 27 (04) :467-478